Pharvaris Highlights Significant Findings on Deucrictibant
ZUG, Switzerland – Pharvaris, a prominent late-stage biopharmaceutical company focusing on innovative therapies for hereditary angioedema (HAE), is set to showcase important findings related to Deucrictibant, an oral bradykinin B2 receptor antagonist. The company announced the acceptance of multiple abstracts for presentation at various upcoming scientific conferences, emphasizing its commitment to addressing the challenges faced by individuals with HAE.
Major Presentations Scheduled
The first significant venue will be the American College of Allergy, Asthma, & Immunology’s Annual Scientific Meeting (ACAAI) in Boston from October 24-28, 2024. During this event, Pharvaris will present seven abstracts focused on the efficacy and safety of Deucrictibant.
Poster Presentations
Among the highlighted presentations at the ACAAI is the long-term safety and efficacy of Deucrictibant for hereditary angioedema prophylaxis. Dr. John Anderson will present findings from the CHAPTER-1 Open-Label Extension Study on October 25, where he will address crucial safety and leading efficacy indicators of this innovative treatment.
Additionally, another abstract from Dr. Anderson will showcase the RAPIDe-2 extension study, shedding light on the effectiveness of Deucrictibant in long-term treatment of HAE attacks. This e-poster session is expected to deep dive into patient outcomes and treatment frameworks.
Scientific Insights from Key Researchers
Dr. Evangelia Pardali will share her expertise on the development of novel biomarker assays for characterizing bradykinin-mediated disorders. This advanced research is pivotal for understanding how Deucrictibant can be effectively employed in clinical settings to benefit HAE patients.
Other notable presentations include innovative research on the Bradykinin Challenge Model by Dr. Juan Bravo, Director of Research, to predict dosage effectiveness for humans based on non-human primate studies. These findings underscore the scientific rigor behind Pharvaris’ approach to HAE treatment.
Further Engagement at Canadian Meetings
Pharvaris will also present at the Canadian Society of Allergy and Clinical Immunology (CSACI) meeting in Banff, Alberta, from November 6-9, 2024. Three critical abstracts have been accepted for poster presentations here, providing further insights into the efficacy and safety of Deucrictibant.
Comprehensive Study Results for HAE Treatment
Among the notable presenters is Dr. William H. Yang, who will discuss the results from the CHAPTER-1 phase 2 trial regarding the bimonthly administration of Deucrictibant, a novel treatment aimed at enhancing both safety profiles and patient quality of life during HAE crises.
Seizing Opportunities in Global Conferences
Moreover, earlier this month, a presentation related to Deucrictibant will occur at the Japanese Society of Allergology (JSA) meeting in Japan. Prof. Michihiro Hide will be sharing insights on the Rapide-3 phase 3 trial design, confirming evidence of its efficacy and safety in diverse patient populations.
Company’s Vision and Future Plans
Pharvaris remains committed to developing effective and easy-to-administer therapies for patients suffering from bradykinin-mediated angioedema. With active enrollment in pivotal Phase 3 studies for on-demand treatments and an upcoming study focused on the prophylaxis of HAE attacks, the company is positioning itself as a leader in innovative HAE therapies.
“Our aim is to create a meaningful impact on the lives of individuals with hereditary angioedema,” said a spokesperson from Pharvaris. “We are excited to share our latest data and insights at these respected scientific platforms and engage with the broader medical community.”
Visit the Investor Section for More Information
As Pharvaris moves forward, detailed information and presentation materials related to their findings will be available on their investor website. This commitment not only underscores their transparency but also their dedication to bringing advanced therapies to the market effectively.
Frequently Asked Questions
What is the focus of Pharvaris as a company?
Pharvaris focuses on developing innovative, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema attacks.
Where will the upcoming presentations take place?
The upcoming presentations will occur at major scientific meetings including ACAAI and CSACI, showcasing Pharvaris' recent findings.
Who are the key researchers presenting the findings?
Notably, Dr. John Anderson and Dr. William H. Yang are among the key researchers presenting significant findings related to Deucrictibant.
What is Deucrictibant?
Deucrictibant is a novel oral bradykinin B2 receptor antagonist developed by Pharvaris aimed at preventing and treating HAE attacks.
How does Pharvaris plan to impact HAE treatment?
Pharvaris aims to offer effective and well-tolerated alternatives to treat HAE attacks, enhancing patient outcomes and quality of life.
